GeneDx Sees Unusually Large Options Volume (NASDAQ:WGS)

GeneDx Holdings Corp. (NASDAQ:WGS) was the target of unusually large options trading on Tuesday. Stock traders bought 6,604 put options on the stock. This represents an increase of approximately 255% compared to the typical volume of 1,861 put options.

More GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: GeneDx reported Q3 earnings of $0.28 per share, above the $0.07 consensus estimate, and revenue of $123.1 million, slightly ahead of the $122.9 million estimate. GeneDx Q3 earnings and revenue estimates
• Neutral Sentiment: GeneDx forecast FY 2026 revenue of $475 million–$490 million, a range that includes the $481.1 million analyst consensus. The midpoint is close to expectations, so the guidance offers limited surprise on its own.
• Negative Sentiment: Reports said shares fell after GeneDx lowered growth targets. Also, Q3 EPS was down from $0.49 a year earlier despite beating the current-quarter estimate, raising questions about growth momentum. GeneDx shares and lowered growth targets

Analyst Ratings Changes

Several equities analysts recently weighed in on WGS shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research note on Monday, November 2nd. Guggenheim lifted their price target on GeneDx from $74.00 to $83.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Canaccord Genuity Group increased their price objective on shares of GeneDx from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Zacks Research downgraded shares of GeneDx from a “strong-buy” rating to a “hold” rating in a report on Friday, October 9th. Finally, BTIG Research reiterated a “buy” rating and issued a $85.00 price target (down from $90.00) on shares of GeneDx in a research report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.14.

GeneDx Trading Down 16.0%

Shares of GeneDx stock traded down $10.52 during mid-day trading on Tuesday, hitting $55.20. 1,053,758 shares of the stock were exchanged, compared to its average volume of 925,062. The company has a current ratio of 3.30, a quick ratio of 3.06 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -15.22 and a beta of 2.00. The company has a 50-day simple moving average of $76.42 and a 200 day simple moving average of $71.15. GeneDx has a twelve month low of $32.21 and a twelve month high of $170.87.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, November 9th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.21. The firm had revenue of $123.10 million for the quarter, compared to the consensus estimate of $122.93 million. GeneDx had a positive return on equity of 4.12% and a negative net margin of 23.41%. During the same period in the prior year, the business posted ($0.27) earnings per share. Research analysts forecast that GeneDx will post -0.41 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Katherine Stueland sold 10,501 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total value of $1,025,002.61. Following the completion of the sale, the chief executive officer owned 115,476 shares in the company, valued at $11,271,612.36. This trade represents a 8.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 3,728 shares of the business’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total transaction of $363,890.08. Following the sale, the chief financial officer directly owned 44,945 shares in the company, valued at approximately $4,387,081.45. This represents a 7.66% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 19,206 shares of company stock valued at $1,808,056. 25.17% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Strs Ohio grew its holdings in GeneDx by 8.7% during the 1st quarter. Strs Ohio now owns 2,500 shares of the company’s stock worth $161,000 after acquiring an additional 200 shares during the last quarter. Pictet Asset Management Holding SA grew its stake in shares of GeneDx by 12.9% during the first quarter. Pictet Asset Management Holding SA now owns 3,300 shares of the company’s stock valued at $212,000 after purchasing an additional 378 shares during the last quarter. Swiss National Bank increased its holdings in shares of GeneDx by 1.0% in the first quarter. Swiss National Bank now owns 40,000 shares of the company’s stock valued at $2,569,000 after purchasing an additional 400 shares in the last quarter. Fifth Third Bancorp acquired a new stake in shares of GeneDx in the first quarter valued at approximately $31,000. Finally, Keebeck Wealth Management raised its position in GeneDx by 13.5% in the 1st quarter. Keebeck Wealth Management now owns 4,310 shares of the company’s stock worth $277,000 after purchasing an additional 513 shares during the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

About GeneDx

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results.

The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk.

Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.